Market Overview

Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader

Share:

Seres
Therapeutics, Inc
. (NASDAQ:MCRB) today announced the appointment of
Meryl Zausner, a seasoned biopharmaceutical executive, to its Board of
Directors. Ms. Zausner brings decades of financial and operational
leadership experience in the pharmaceutical industry.

"Meryl Zausner is a highly accomplished financial and strategic leader,
and I am delighted to welcome her to the Seres Board," said Roger J.
Pomerantz, M.D., President, CEO and Chairman of Seres. "Meryl's
extensive biopharmaceutical and oncology expertise will be an important
asset to Seres as we continue to advance our extensive pipeline of
microbiome therapeutic candidates."

Ms. Zausner commented: "I am eager to contribute to Seres' progress as
it advances the development of microbiome therapeutics, a promising new
treatment modality with potential to address a wide range of serious
diseases."

Meryl Zausner previously served as chief financial and administrative
officer of Novartis Pharmaceuticals Corporation and a member of the U.S.
Pharmaceutical Executive Committee and Global Finance Leadership Team.
At Novartis, she was instrumental in the launch of the Oncology Business
Unit, as well as the company's shared services organization. Ms. Zausner
was a member of the Novartis Global Oncology Leadership Team and played
a key role in developing and commercializing leading therapies including
Gleevec® (imatinib). Ms. Zausner is also currently a board member and
chair of the audit committee for Neon Therapeutics, Inc. and the
Multiple Myeloma Research Foundation. Ms. Zausner received a B.S. in
accounting and economics from the University at Albany, SUNY.

About Seres Therapeutics

Seres Therapeutics, Inc. (NASDAQ:MCRB) is a leading microbiome
therapeutics platform company developing a novel class of biological
drugs that are designed to treat disease by restoring the function of a
dysbiotic microbiome, where the state of bacterial diversity and
function is imbalanced. Seres' lead program, SER-109, has obtained
Breakthrough Therapy and Orphan Drug designations from the U.S. Food and
Drug Administration and is in Phase 3 development for multiply recurrent C.
difficile
infection. SER-287 has successfully completed a Phase 1b
study in patients with mild-to-moderate ulcerative colitis. Seres is
developing SER-262, the first ever synthetic microbiome therapeutic
candidate, in a Phase 1b study in patients with primary C. difficile
infection. Seres is also developing SER-401 to augment the efficacy of
immuno-oncology treatment. For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.

Forward Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements contained in this press release that do not relate to matters
of historical fact should be considered forward-looking statements,
including Ms. Zausner's potential contribution to the Company.

These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements,
including, but not limited to, the following: we have incurred
significant losses, are not currently profitable and may never become
profitable; our need for additional funding; our limited operating
history; our unproven approach to therapeutic intervention; the lengthy,
expensive, and uncertain process of clinical drug development; our
reliance on third parties and collaborators to conduct our clinical
trials, manufacture our product candidates, and develop and
commercialize our product candidates, if approved; our lack of
experience in manufacturing, selling, marketing, and distributing our
product candidates; failure to compete successfully against other drug
companies; protection of our proprietary technology and the
confidentiality of our trade secrets; potential lawsuits for, or claims
of, infringement of third-party intellectual property or challenges to
the ownership of our intellectual property; our patents being found
invalid or unenforceable; our ability to retain key personnel and to
manage our growth; the potential volatility of our common stock; and our
management and principal stockholders have the ability to control or
significantly influence our business. These and other important factors
discussed under the caption "Risk Factors" in our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission, or SEC, on
August 2, 2018 and our other reports filed with the SEC, including the
Quarterly Report we intend to file later today, could cause actual
results to differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management's estimates as of the date of this press
release. While we may elect to update such forward-looking statements at
some point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change. These forward-looking
statements should not be relied upon as representing our views as of any
date subsequent to the date of this press release.

View Comments and Join the Discussion!